← Back to headlines
Amgen Q2 Earnings Preview Focuses on New Drug Growth
An earnings preview for Amgen's second quarter suggests that growth from its newer drugs is expected to counteract declines in its legacy portfolio.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
